Evidence map›Paper›PMID 21940749›Full record

ArticleCancer research2011

A comprehensive view of nuclear receptor cancer cistromes.

Qianzi Tang, Yiwen Chen, Clifford Meyer, Tim Geistlinger, Mathieu Lupien, Qian Wang, Tao Liu, Yong Zhang, Myles Brown, Xiaole Shirley Liu

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 144 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Genetics of cancer therapy-associated cardiotoxicity.Journal of molecular and cellular cardiology · 2022
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Qianzi TangDepartment of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai, China.
Yiwen Chen
Clifford Meyer
Tim Geistlinger
Mathieu Lupien
Qian Wang
Tao Liu
Yong Zhang
Myles Brown
Xiaole Shirley Liu
Dana-Farber Cancer Institute · USTongji University · CNHarvard University · US

Funding

ProteomicsU19DK062434 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI O'MALLEY, BERT W · 2002 to 2011
$37.4M
Comprehensive Analysis of Estrogen Receptor Genomic ActionR01DK074967 · NIDDK · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2007 to 2011
$2.9M
Comprehensive Analysis of Estrogen Receptor Genomic ActionR56DK074967 · NIDDK · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2006 to 2006
$420k
NIDDK NIH HHS DK062434NIDDK NIH HHS DK074967NIDDK NIH HHS R01 DK074967NIDDK NIH HHS R56 DK074967NIDDK NIH HHS U19 DK062434
6 · The paper itself

Abstract

Nuclear receptors comprise a superfamily of ligand-activated transcription factors that play important roles in both physiology and diseases including cancer. The technologies of chromatin immunoprecipitation followed by array hybridization (ChIP-chip) or massively parallel sequencing (ChIP-seq) has been used to map, at an unprecedented rate, the in vivo genome-wide binding (cistrome) of nuclear receptors in both normal and cancer cells. We developed a curated database of 88 nuclear receptor cistrome data sets and other associated high-throughput data sets including 121 collaborating factor cistromes, 94 epigenomes, and 319 transcriptomes. Through integrative analysis of the curated nuclear receptor ChIP-chip/seq data sets, we discovered novel factor-specific noncanonical motifs that may have important regulatory roles. We also revealed a common feature of nuclear receptor pioneering factors to recognize relatively short and AT-rich motifs. Most nuclear receptors bind predominantly to introns and distal intergenetic regions, and binding sites closer to transcription start sites were found to be neither stronger nor more evolutionarily conserved. Interestingly, while most nuclear receptors appear to be predominantly transcriptional activators, our analysis suggests that the binding of ESR1, RARA, and RARG has both activating and repressive effects. Through meta-analysis of different omic data of the same cancer cell line model from multiple studies, we generated consensus cistrome and expression profiles. We further made probabilistic predictions of the nuclear receptor target genes by integrating cistrome and transcriptome data and validated the predictions using expression data from tumor samples. The final database, with comprehensive cistrome, epigenome, and transcriptome data sets and downstream analysis results, constitutes a valuable resource for the nuclear receptor and cancer community.

Indexed as

EpigenomicsTranscriptomeAnimalsBinding SitesChromatin ImmunoprecipitationEvolution, MolecularHumansMiceNeoplasmsNucleotide MotifsReceptors, Cytoplasmic and NuclearResponse ElementsReceptors, Cytoplasmic and Nuclear

Identifiers

PMID21940749
PMCPMC3610570
OpenAlexW2116591973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.